Kinnate Biopharma, Inc. (KNTE)
| Market Cap | 1.66B |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -26.00M |
| Shares Out | 41.53M |
| EPS (ttm) | -0.63 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | January 15 |
| Last Price | $38.30 |
| Previous Close | $40.00 |
| Change ($) | -1.70 |
| Change (%) | -4.25% |
| Day's Open | 40.05 |
| Day's Range | 38.05 - 40.00 |
| Day's Volume | 72,956 |
| 52-Week Range | 36.35 - 45.25 |
Osmotica Pharmaceuticals (NASDAQ: OSMT) shares were trading higher Monday in anticipation of a ruling by the FDA on the company's New Drug Application for Arbaclofen ER in patients with multip...
Kinnate Biopharma Inc (NASDAQ: KNTE), which focuses on developing small-molecule kinase inhibitors for difficult-to-treat, genomically-defined cancers, recently raised $276 million in gross pr...
SAN FRANCISCO and SAN DIEGO, Dec. 07, 2020 (GLOBE NEWSWIRE) -- Kinnate Biopharma Inc. (Nasdaq: KNTE) (“Kinnate”), a biopharmaceutical company focused on the discovery and development of small ...
The first week of the December IPO market saw eight IPOs and ten SPACs raise $3.9 billion, led by Chinese education technology group 17 Education & Technology Group. Two companies, Ondas and A...
KNTE stock has rocketed higher by as much as 115% following the Kinnate Biopharma IPO. Here's what you should know right now.
Kinnate Biopharma shares more than doubled in their trading debut Thursday, after the company upsized its initial public offering and priced it above its proposed range. The stock, trading on ...
Kinnate Biopharma is a preclinical biotech focused on the discovery and development of small molecule kinase inhibitors for difficult-to-treat cancers. The IPO raised $240 million.
Kinnate Biopharma upsized its initial public offering on Wednesday and priced it at $20 a share, above its $18 to $19 proposed price range. The company sold 12 million shares, or more than the...
SAN FRANCISCO and SAN DIEGO, Dec. 02, 2020 (GLOBE NEWSWIRE) -- Kinnate Biopharma Inc. (Nasdaq: KNTE) (“Kinnate”), a biopharmaceutical company focused on the discovery and development of small ...
Kinnate Biopharma set terms for its initial public offering on Wednesday with plans to offer 11.5 million shares priced at $18 to $19 each. The company would raise $218.5 million at the top of...
The firm is developing treatments for various cancers using a kinase inhibitory approach.
Kinnate Biopharma, an oncology biotech developing small molecule kinase inhibitors, filed on Friday with the SEC to raise up to $100 million in an initial public offering.
Kinnate Biopharma, Inc. has filed to go public with an IPO on the NASDAQ.
About KNTE
Kinnate Biopharma, a biopharmaceutical company, focuses on the discovery and development of small molecule kinase inhibitors for treating genomically defined cancers. The company's lead product candidate is KIN002787, which is a rapidly accelerated fibrosarcoma inhibitor that is in preclinical stage for the treatment of patients with lung cancer, melanoma, and other solid tumors. Its other products in preclinical stage include KIN003, which are small-molecule kinase inhibitors that target cancer-associated alterations in fibroblast growth facto... [Read more...]
| Industry Biotechnology | IPO Date Dec 3, 2020 |
| CEO Nima Farzan | Employees 27 |
| Stock Exchange NASDAQ | Ticker Symbol KNTE |
Analyst Forecasts
According to 4 analysts, the average rating for KNTE stock is "Buy." The 12-month stock price forecast is 52.00, which is an increase of 35.77% from the latest price.